Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S253010, C514S254020, C514S254030, C514S253060, C514S254110, C514S255010, C514S412000, C514S326000, C514S354000, C544S295000, C544S360000, C544S363000, C544S367000, C544S369000, C544S374000, C544S376000, C544S379000, C544S391000, C544S395000, C546S207000, C546S209000, C546S283700, C546S323000, C546S328000, C548S453000
Reexamination Certificate
active
08008302
ABSTRACT:
The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
REFERENCES:
patent: 7786121 (2010-08-01), Pain et al.
patent: 2002/0115863 (2002-08-01), Patel et al.
patent: WO 94/02447 (1994-02-01), None
patent: 95/33731 (1995-12-01), None
patent: WO 98/33788 (1998-08-01), None
patent: WO 01/83461 (2001-11-01), None
patent: 03/084941 (2003-10-01), None
patent: 2005/019194 (2005-03-01), None
Birkedal-Hansen et al. Critical Reviews in Oral Biology and Medicine, vol. 4(2), p. 197-250 (1993).
Vincenti et al. Arthritis & Rheumatism vol. 17, p. 1115-1124 (1994).
Belvisi, M. G. et al., “The role of matrix metalloproteinases (MMPs) in the patho-physiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?” Inflamm. res., vol. 52, pp. 95-100, 2003.
Bulbena, O. et al., “Cytoprotective Activity in the Gastric Mucosa of Rats Exposed to Carbon Tetrachloride-Induced Liver Injury”, Inflammation, vol. 21, No. 5, pp. 475-488, 1997.
Clark, Ian M. at al., “Metalloproteinases: their role in arthritis and Potential as therapeutic targets”, Expert Opin. Ther. Targets, vol. 7, No. 1, pp. 19-34, 2003.
Doherty, Terence M. et al., “Therapeutic developments in matrix metalloproteinase inhibition”, Expert Opin. Ther. Patents, vol. 12, No. 5, pp. 665-707, 2002.
Fingleton, Barbara, “Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects”, Expert Opin. Ther. Targets, vol. 7, No. 3, pp. 385-397, 2003.
Galis, Zorina S. et al., “Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis The Good, the Bad, and the Ugly”, Circulation Research, vol. 90, pp. 251-262, 2002.
Henrotin, Yet al., “The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives”, Expert Opin. Ther. Patents, vol. 12, No. 1, pp. 29-43, 2002.
Hooper, Nigel M. et al., “Membrane protein secretases”, Biochem. J., vol. 321, pp. 265-279, 1997.
Horstmann, Solveig at al., “Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients influlence of Diffierent Therapies”, Stroke, vol. 34, pp. 2165-2172, 2003.
Tervahartiala, Ingman T. et al., “Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients”, J Clin Periodontal, vol. 23, pp. 1127-1132, 1996.
Knight, C. Graham et al., “A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases”, Febs Letters, vol. 296, No. 3, pp. 263-266, Jan. 1992.
Krishna, Ganesh et al., “New therapies for chronic obstructive pulmonary disease”, Expert Opin. Investig. Drugs vol. 13, No. 3, pp. 255-267, 2004.
Leppert, David et al., “Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis”, Brain Research Reviews, vol. 36, pp. 249-257, 2001.
Mahboobi, Siavosh et al., “214. Synthesis of Esters of 3-(2-Aminoethy1)-1H-Indole-2-acetic Acid and 3-(2-Aminoethyl)-1H-indole-2-malonic Acid (=2-[3(2-Aminoethyl)-1H-indol-2-y1]propanediolc Acid)”, Helvetica Chi mica Acta, vol. 71, pp. 2034-2041, 1988.
Makrakis, E. et al., “Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinsase-1 in plasma/serum and urine of women during term and threatened preterm labor: a clinical approach”, The Journal of Maternal-Fetal and Neonatal Medicine, vol. 14, pp. 170-176, 2003.
Malamas, Michael S. et al., Novel Benzofuran and Benzothiophene Biphenyls as Inhibitors of Protein Tyrosine Phosphatase 1 B with Antihyperglycemic Properties, J. Med. Chem., vol. 43, No. 7, pp. 1293-1310, 2000.
Opdenakker, Ghislain et al., “Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis”, The Lancet Neurology, vol. 2, pp. 747-756, Dec. 2003.
Peterson, J, Thomas, “Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery”, Heart Failure Reviews, vol. 9, pp. 63-79, 2004.
Seebach, Dieter, et al. “Diastereoselective α-Alkylation of β-Hydroxycarboxylic Esters Through Alkoxide Enolates: Diethyl (2S, 3R)-(+)-3-Ailyl-2-Hydroxysuccinate from Diethyl (S)-( -31 )Malate”, Organic Syntheses Collective vol. III, pp. 153-159, 1990.
Skiles, Jerry W. et al., “The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors”, Current Medicinal Chemistry, vol. 8, No. 4, pp. 425-474, 2001.
Skotnicki, Jerauld S. et al., “Design strategies for the identification of MMP-13 and TACE inhibitors”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 742-759, 2003.
Visse, Robert et al., “Matrix Meatlloproteinases and Tissue Inhibitors of Metalloproteinases Structure, Function, and Biochemistry”, Circulation Research, vol. 92, pp. 827-839, 2003.
Vos, Catharine M.P. et al., “Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions”, Journal of Neuroimmunology, vol. 138, pp. 106-114, 2003.
Wada, Carol K. et al., “Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors”, J. Med. Chem., vol. 45, No. 1, pp. 219-232, 2002.
Bombrun Agnes
Crosignani Stefano
Gerber Patrick
Gonzalez Jerome
Jorand-Lebrun Catherine
Bernhardt Emily
Merck Serono SA
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
N-hydroxyamide derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-hydroxyamide derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-hydroxyamide derivatives and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772511